Bio-Rad Laboratories Statistics
Total Valuation
BIO has a market cap or net worth of $6.98 billion. The enterprise value is $6.69 billion.
Important Dates
The last earnings date was Thursday, May 1, 2025, after market close.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BIO has 27.21 million shares outstanding. The number of shares has decreased by -3.01% in one year.
| Current Share Class | 22.14M |
| Shares Outstanding | 27.21M |
| Shares Change (YoY) | -3.01% |
| Shares Change (QoQ) | -0.15% |
| Owned by Insiders (%) | 16.50% |
| Owned by Institutions (%) | 75.89% |
| Float | 18.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 29.50 |
| PS Ratio | 2.84 |
| Forward PS | 2.69 |
| PB Ratio | 1.06 |
| P/TBV Ratio | 1.17 |
| P/FCF Ratio | 19.65 |
| P/OCF Ratio | 13.56 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 15.68, with an EV/FCF ratio of 18.83.
| EV / Earnings | n/a |
| EV / Sales | 2.63 |
| EV / EBITDA | 15.68 |
| EV / EBIT | 24.41 |
| EV / FCF | 18.83 |
Financial Position
The company has a current ratio of 5.99, with a Debt / Equity ratio of 0.21.
| Current Ratio | 5.99 |
| Quick Ratio | 4.14 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 2.77 |
| Debt / FCF | 3.85 |
| Interest Coverage | 5.64 |
Financial Efficiency
Return on equity (ROE) is -27.51% and return on invested capital (ROIC) is 1.85%.
| Return on Equity (ROE) | -27.51% |
| Return on Assets (ROA) | 1.55% |
| Return on Invested Capital (ROIC) | 1.85% |
| Return on Capital Employed (ROCE) | 3.04% |
| Revenue Per Employee | $330,013 |
| Profits Per Employee | -$281,052 |
| Employee Count | 7,700 |
| Asset Turnover | 0.23 |
| Inventory Turnover | 1.50 |
Taxes
| Income Tax | -586.10M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.98% in the last 52 weeks. The beta is 1.00, so BIO's price volatility has been similar to the market average.
| Beta (5Y) | 1.00 |
| 52-Week Price Change | -8.98% |
| 50-Day Moving Average | 245.39 |
| 200-Day Moving Average | 310.55 |
| Relative Strength Index (RSI) | 58.43 |
| Average Volume (20 Days) | 321,314 |
Short Selling Information
The latest short interest is 1.07 million, so 3.94% of the outstanding shares have been sold short.
| Short Interest | 1.07M |
| Short Previous Month | 710,390 |
| Short % of Shares Out | 3.94% |
| Short % of Float | 5.75% |
| Short Ratio (days to cover) | 2.81 |
Income Statement
In the last 12 months, BIO had revenue of $2.54 billion and -$2.16 billion in losses. Loss per share was -$77.10.
| Revenue | 2.54B |
| Gross Profit | 1.36B |
| Operating Income | 274.20M |
| Pretax Income | -1.73B |
| Net Income | -2.16B |
| EBITDA | 426.80M |
| EBIT | 274.20M |
| Loss Per Share | -$77.10 |
Full Income StatementBalance Sheet
The company has $1.66 billion in cash and $1.37 billion in debt, giving a net cash position of $290.90 million or $10.69 per share.
| Cash & Cash Equivalents | 1.66B |
| Total Debt | 1.37B |
| Net Cash | 290.90M |
| Net Cash Per Share | $10.69 |
| Equity (Book Value) | 6.68B |
| Book Value Per Share | 241.72 |
| Working Capital | 2.53B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $515.30 million and capital expenditures -$159.80 million, giving a free cash flow of $355.50 million.
| Operating Cash Flow | 515.30M |
| Capital Expenditures | -159.80M |
| Free Cash Flow | 355.50M |
| FCF Per Share | $13.06 |
Full Cash Flow StatementMargins
Gross margin is 53.64%, with operating and profit margins of 10.79% and -85.16%.
| Gross Margin | 53.64% |
| Operating Margin | 10.79% |
| Pretax Margin | -108.23% |
| Profit Margin | -85.16% |
| EBITDA Margin | 16.80% |
| EBIT Margin | 10.79% |
| FCF Margin | 13.99% |
Dividends & Yields
BIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.01% |
| Shareholder Yield | 3.01% |
| Earnings Yield | -30.98% |
| FCF Yield | 5.09% |
Dividend DetailsAnalyst Forecast
The average price target for BIO is $330.50, which is 28.76% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $330.50 |
| Price Target Difference | 28.76% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 3.67% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on March 8, 2002. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 8, 2002 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
BIO has an Altman Z-Score of 3.65 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.65 |
| Piotroski F-Score | 5 |